December 6th at 8am PDT | 11am EDT | 4pm BST | 5pm CEST
The primary method for characterization and quantitation of synthetic oligonucleotides is liquid chromatography-mass spectrometry (LC-MS). Whether for characterizing process and product-related impurities or bioanalytical pharmacokinetic studies, improving method sensitivity is of critical importance. In this presentation, we discuss how LC-MS sensitivity can be improved with mobile phase optimization and column selection. We also demonstrate how one can minimize adduct formation and improve ionization efficiency, which can improve MS sensitivity for improved characterization and quantitation data. We have developed novel automatic identification of process-related impurities using high resolution MS (HRMS), new LC columns for oligo analysis, and novel deconvolution / mass-matching software. The methods enable precise characterization of diverse oligonucleotides, with every oligo examined to date (15 independent oligos) having been successfully analyzed.
Key Learning Objectives:
Who Should Attend:
Larry Brill, PhD
Senior Scientist Phenomenex - Biologics
Laurence M. Brill, Ph.D. is a Sr. Application Scientist, BioPharma at Phenomenex. He has established and developed LCMS-based protein and oligonucleotide analysis methods under several different conditions. He is leading a growing team in these large molecule analyses and others that are under development.
Previously, he was a Principal and Sr. Scientist for Bioanalytical & Protein LCMS at Intertek, Sr. Scientist and Director of Proteomics at Sanford Burnham Medical Research Institute, a Postdoctoral Associate and Principal Investigator at the Genomics Institute of the Novartis Research Foundation, and a Postdoctoral Fellow at the Scripps Research Institute.
Maria Basanta - Sanchez. PhD
Maria Basanta -Sanchez joined Protein Metrics in 2019 as a Manager of Western US Sales. Before Maria joined industry, she was a scientist with 10+ yearsof analytical researchwith an unbounded focus on personalized medicine, biomarker discovery, clinical applications and oligonucleotide research. She received her PhD from The University of Manchester, UK.Prior to Protein Metrics she was a Senior Application Scientist at Waters Corporationin the Biopharma division